



DFE
pharma

Oral Solid Dose

TECHNICAL PAPER OF **SUPERDISINTEGRANTS**

Superdisintegrants and their
working mechanisms



Pauline H.M. Janssen¹ and Frank Fox¹

¹ DFE Pharma, Kleverstrasse 187, Goch , Germany

Superdisintegrants and their working mechanisms

Disintegrants and superdisintegrants are well-known excipients that are used in the formulation of oral dosage forms. They promote disintegration of tablets and capsule slugs when placed in an aqueous environment. Disintegration is the process of breaking up a dosage form in smaller particles to increase the available surface area. It is important as tablet disintegration could determine the drug availability for dissolution and subsequently absorption. There are many factors in a formulation that affect the disintegration of a dosage form. These include proportion of the disintegrant, type of tablet matrix, solubility of tablet matrix, hardness of tablet, API dose, API properties, tablet's porosity, and the working mechanism. The main mechanisms of disintegration are swelling, wicking and deformation.

Mechanisms of action

Promotion of disintegration in a formulation can be achieved by the addition of a disintegrant or superdisintegrant. Five mechanisms of action are proposed for (super-) disintegrants: heat of wetting, particle repulsion, wicking/capillary action, swelling and deformation recovery (Carmella et al., 1988, Bele & Derle, 2012). It is believed that no single mechanism is responsible for the action of disintegrants, but that disintegration is the results of inter-relationships between these mechanisms. The most widely accepted mechanisms are swelling, wicking and deformation recovery (Joshi et al., 2015).

Swelling

The most accepted working mechanism for tablet disintegration is by swelling. Swelling is the result of absorbed solution. It is associated with multi-dimensional amplification where particles enlarge in all directions to create an internal pressure. This pressure pushes apart adjoining components and the matrix breaks when the adhesiveness of ingredients is overcome (Desai, Liew & Heng, 2016).

For swelling disintegrants, porosity of tablets could have a big impact on disintegration performance. A porous tablet matrix with large void spaces could reduce the impact of swelling and impede their efficiency in tablet disintegration. On the other hand, low porosity compacts could hinder liquid entry and prolong disintegration as well (Desai, Liew & Heng, 2016).

Wicking (capillary action)

Wicking may be defined as the phenomenon of drawing water into the tablet due to the presence of hydrophilic groups. It is the capillary action by which water penetrates a tablet through the porous structure of the disintegrant. Disintegrants with low cohesiveness and low compressibility provide tablet porosity with pathways for the penetration of fluid into the tablets (Mohanachandran, Sindhumol, & Kiran, 2011). As water is pulled into the structure, the physical bonds between the dosage components is reduced and the matrix falls apart, as indicated in Figure 1.




Figure 1

Wicking: water is pulled into the pores by disintegrant and reduce the physical bonding forces between particles.

Deformation / strain recovery

Strain recovery is the reversible process of deformation. It is the result of plastic deformation of disintegrants that are believed to be elastic in nature. During compaction, the particles of these disintegrants deform and interparticle bonds are formed. When these compacted disintegrants come in contact with the aqueous media however, mechanical activation helps to partially recover their original shapes (Desai, Liew & Heng, 2016). By returning to the original state, a pressure within the tablet matrix is obtained, resulting in disintegration (Shihora & Panda, 2011).

Solani amyllum is an example of a disintegrant with deformation mechanism. It is a native potato starch and can be used in a concentration of 3-15%w/w in a tablet formulation as a disintegrant. Solani amyllum is more effective when used with high compaction pressures, because of the higher deformation for the potato starch particles, making the strain recovery stronger (Szabó-Révész & Szepes, 2009).

Superdisintegrants used in dosage forms

Disintegrants are commonly classified in literature as traditional disintegrants and superdisintegrants (Moreton, 2008). Traditional disintegrants include native starches, alginic acid, ion exchange resins and microcrystalline cellulose.

The term superdisintegrants was introduced shortly after sodium starch glycolate, croscarmellose sodium and crospovidone became available. Superdisintegrants have improved efficiency and

facilitate faster disintegration with smaller quantity, compared to regular disintegrants. Commonly used superdisintegrants are highly efficient at low concentration levels (2-5%w/w).

Sodium starch glycolate – Primojel®

The first introduced superdisintegrant in the market was sodium starch glycolate (SSG). Figure 2 shows a SEM picture of Primojel®, DFE Pharma's sodium starch glycolate. It is produced via a two-step reaction, starting with a potato starch structure.

The first reaction step involves introduction of cross links across the amylose and amylopectin chains. The function of the cross-links is to reduce the water-soluble fraction and the viscosity of the substituted starch in water. Crosslinks in SSG provide high spacing between the chains, facilitating water penetration and swelling. A second step is carboxymethylation, which involves the substitution of hydroxyl groups by sodium carboxymethyl ester groups. This substitution disrupts hydrogen bonding within the polymer structure, resulting in the ability to take up large amounts of water without the formation of a gel.

This unique structure of SSG makes that compared to other types of superdisintegrants, SSG has the highest swelling value (see Figure 3). Primojel® can take up more than 20 times its own weight of water and it swells in three dimensions. Rapid water penetration into the tablets and powerful swelling results in rapid disintegration.




Figure 2
SEM picture of Primojel®




Figure 3
Swelling values of SSG, CCS and crospovidone after 20min dispersion of 500mg of each superdisintegrant in 10mL of 0.1N HCl (pH=1) and in 10mL of phosphate buffer (pH=6.8) at room temperature. Adapted from Zarnpi et al. 2017.

The swelling action makes Primojel® most effective in non-soluble matrices. With soluble or partially soluble matrix components, the matrix is dissolving and thus the disintegrant is deprived of some of what it might push against, thus reducing the disintegrant effect (Moreton, 2008).

Croscarmellose sodium – Primellose®

Croscarmellose sodium is a cross-linked polymer of carboxymethyl cellulose. It is manufactured from high quality wood pulp or cotton liners. Figure 4 shows a SEM picture of Primellose®, which originates from cotton liner.




Figure 4
SEM picture of Primellose®.

The production of Primellose® starts with carboxy-methylation of cellulose chains. This step reduces the hydrogen bonds in the cellulose chains, resulting in a porous structure. A second step is cross-linking, which in this case is not performed by an external agent, but via some of the carboxy-methyl groups themselves. The degree of cross-linking is related to two properties of the disintegrant, namely the water-soluble content and the settling volume. Both these parameters reduce as the degree of cross-linking increases.

Croscarmellose sodium appears to act partly through swelling, but it only swells in two directions (Mohanachandran, Sindhumol & Kiran, 2011). The main working mechanism of CCS is wicking, evidenced by the fibrous particle shape. The long fibres will function over a longer distance in the tablet matrix and thereby cause disruption over a longer distance than croscopovidone or SSG particles (Morton, 2018).

Figure 5 shows the disintegration time of placebo lactose tablets with different concentrations of SSG (Primojel®) and CCS (Primellose®). In soluble matrices, CCS often is most effective in getting the lowest disintegration times. The figure also shows the impact of filler-binder on the disintegration of a tablet. When disintegration of the tablet is critical, SuperTab® 30GR is the preferred type of lactose as a filler-binder.




Figure 5
Disintegration times of placebo tablets formulated with different concentrations of Primojel® (SSG) and Primellose® (CCS). Round tablets (9mm) of 250mg are compressed to 100N hardness. From the different types of filler-binders, SuperTab® 30GR is disintegrating the most effective.

Crospovidone

Crospovidone is a cross-linked polyvinylpyrrolidone. This polymer is also known as a 'popcorn' polymer, as it possesses a popped structure like indicated in Figure 6.




Figure 6
SEM picture of polyplasdone XL-10, adapted from Shah & Augsburger, 2001.

The production of crospovidone is performed by proliferous polymerization of vinylpyrrolidone (Barabas & Adeyeye, 1996). This process takes place via a free radical, which can be developed through rupture of some polymer chains or it can be introduced via a free radical initiator. The growth of chains can be initiated at multiple positions, and is therefore not limited to one position, which often results in high degrees of cross-linking.

No clear consensus on the working mechanism of crospovidone exists. Wicking followed by secondary swelling was proposed by some first (Kornblum & Stoopak, 1973), while others propose high swelling pressure as the disintegration mechanism (Shu et al., 2002). Strain recovery is also mentioned in literature as the main disintegration mechanism of crospovidone (Quodbach et al., 2014). Although unclarity exists on the exact working mechanism, crospovidone is generally considered as a very effective superdisintegrant. A potential drawback

of crospovidone however, is that it can contain traces of formaldehyde and peroxides which may have implications for compatibility with other components in the formulation (Morton, 2008).


Considerations in selecting disintegrant type

Tablet disintegration is a complex process which is influenced by many factors, including the disintegrant mode of action, proportion of the disintegrant, type of tablet matrix, solubility of tablet matrix, hardness of tablet, API dose, API properties, and tablet porosity (Shihora & Panda, 2011). Because of the interplay of these factors, it is impossible to predict which type of disintegrant will provide the fastest disintegration in a specific formulation (Shegokar & Wiebinga, 2015).

Recommendations for selection of disintegrants are sometimes based on solubility of the tablet matrix. A swellable superdisintegrant, like Primojel[®], is often recommended for non-soluble matrices. The disintegrant effect could be reduced in soluble matrices, because the dissolution of soluble matrix components results in a situation where the disintegrant is deprived of some what it might push against (Moreton, 2008). Disintegrants with wicking mechanism, like Primellose[®], are often recommended in soluble matrices. This is because it enables fast distribution of water throughout the tablet matrix, leading to rapid dissolution of soluble matrix components.

The final choice of formulators often tends to be based on experience and chemistry rather than functionality. Key for formulators is to develop a robust formulation that is safe, efficient and of high quality. Robust formulations should be able to accommodate typical variation seen in API, excipient, and process without the manufacture, stability or performance of the product to be compromised. The use of consistent, low variable, excipients is recommended to reduce costs and time of development. With Primojel[®] and Primellose[®], DFE Pharma provides disintegrants having proven consistency of the relevant functional related characteristics.

Primojel®



Primellose®




Figure 7

Consistency of functional related characteristic of Primojel® (top) and Primellose® (bottom) for 11 batches released in the year 2019. Dashed lines represent product specification limits. For the particle size measurements an airjet sieve is used. All potential functional related characteristics show a consistent measurement value.

Conclusion

Disintegration of tablets is required for the drug availability for dissolution and subsequently absorption. Superdisintegrants promote disintegration and can have different working mechanisms, including swelling and wicking. A formulation scientist requires a good understanding of the working mechanisms of different types of disintegrants. Primojel® is a sodium starch glycolate, which has the highest swelling value of the

superdisintegrants and can take up more than 20 times its own weight of water. Primellose® is croscarmellose sodium and the wicking of the fibrous particles allows quick penetration of fluid into tablets. Key for all disintegrants is that they have to provide consistently good disintegration. DFE Pharma has proven consistency for their superdisintegrants Primojel® and Primellose®.

References

1. Barabas, E. S., & Adeyeye, C. M. (1996). Crospovidone. In *Analytical profiles of drug substances and excipients* (Vol. 24, pp. 87-163). Academic Press.
2. Bele, M. H., & Derle, D. V. (2012). Mechanism of disintegrant action of polacrillin potassium: Swelling or wicking?. *Acta Pharmaceutica Sinica B*, 2(1), 70-76.
3. Caramella, C., Colombo, P., Conte, U., Ferrari, F., Gazzaniga, A., LaManna, A., & Peppas, N. A. (1988). A physical analysis of the phenomenon of tablet disintegration. *International journal of pharmaceuticals*, 44(1-3), 177-186.
4. Desai, P. M., Liew, C. V., & Heng, P. W. S. (2016). Review of disintegrants and the disintegration phenomena. *Journal of pharmaceutical sciences*, 105(9), 2545-2555.
5. Joshi, Y., Mastropietro, D., Muppalaneni, S., & Omidian, H. (2015). A new approach to determining the performance of superdisintegrants. *Journal of Bioactive and Compatible Polymers*, 30(1), 3-16.
6. Kornblum SS, Stoopak SB. A new tablet disintegrating agent: cross-linked polyvinylpyrrolidone. *J Pharm Sci*. 1973;62(1):43-49. 52.
7. Mohanachandran, P. S., Sindhumol, P. G., & Kiran, T. S. (2011). Superdisintegrants: an overview. *International journal of pharmaceutical sciences review and research*, 6(1), 105-109.
8. Moreton, R. C. (2008). Disintegrants in tableting. In *Pharmaceutical Dosage Forms- Tablets* (pp. 233-266). CRC Press.
9. Quodbach, J., Moussavi, A., Tammer, R., Frahm, J., & Kleinebudde, P. (2014). Tablet disintegration studied by high-resolution real-time magnetic resonance imaging. *Journal of pharmaceutical sciences*, 103(1), 249-255. <https://doi.org/10.1002/jps.23789>.
10. Shah, U., & Augsburger, L. (2001). Evaluation of the functional equivalence of crospovidone NF from different sources. I. Physical characterization. *Pharmaceutical development and technology*, 6(1), 39-51.
11. Shegokar, J. & Wiebinga, C. Eye on Excipients. As appeared in *Tablets & Capsules* October 2015.
12. Shihora, H., & Panda, S. (2011). Superdisintegrants, utility in dosage forms: a quick review. *JPSBR*, 1(3), 148-153.
13. Shu, T., Suzuki, H., Hironaka, K., & Ito, K. (2002). Studies of rapidly disintegrating tablets in the oral cavity using co-ground mixtures of mannitol with crospovidone. *Chemical and pharmaceutical bulletin*, 50(2), 193-198.
14. Szabó-Révész, P., & Szepes, A. (2009). Potato Starch in Pharmaceutical Technology—A Review.
15. Zarmpi, P., Flanagan, T., Meehan, E., Mann, J., & Fotaki, N. (2017). Biopharmaceutical aspects and implications of excipient variability in drug product performance. *European Journal of Pharmaceutics and Biopharmaceutics*, 111, 1-15.
16. Zhao, N., & Augsburger, L. L. (2005). Functionality comparison of 3 classes of superdisintegrants in promoting aspirin tablet disintegration and dissolution. *AAPS pharmscitech*, 6(4), E634-E640.

Head Office

Kleber Strasse 187
P.O. Box 20 21 20
47568 Goch
Germany
T. +49 2823 9288 770
F. +49 2823 9288 7799
pharma@dfepharma.com

DFE Pharma GmbH & Co. KG - Warranty
The details given here are merely intended for information purposes and are in no way legally binding.
Consequently we accept no responsibility in the broadest sense of the word for damage that may
result from applications based upon this information. Furthermore, this information does not constitute
permission to infringe patent and licence rights.